NCT07215858View on ClinicalTrials.gov

BPL-1357 Against H1N1 Influenza Virus Challenge

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

March 2, 2026

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2028

Conditions
InfluenzaHuman
Interventions
BIOLOGICAL

BPL-1357 IM

Quadrivalent, inactivated, whole-virus vaccine containing 4 different wild-type avian viruses given intramuscularly.

BIOLOGICAL

BPL-1357 IN

Quadrivalent, inactivated, whole-virus vaccine containing 4 different wild-type avian viruses given intranasally.

OTHER

Placebo IM

Placebo given intramuscularly.

OTHER

Placebo IN

Placebo given intranasally.

Trial Locations (2)

20892

National Institutes of Health Clinical Center, Bethesda

77555

University of Texas Medical Branch, Galveston, Galveston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH